Grâce à nos données, nous soutenons la recherche dans le domaine des maladies rhumatismales inflammatoires. Vous trouverez ici un aperçu des projets de recherche en cours.
Si vous souhaitez en savoir plus sur un projet en cours, veuillez contacter notre Direction scientifique, Catherine Raptis.
| Numéro de projet | Titre | Chef de projet |
|---|---|---|
| 2014_08 | The effect of body mass index on the course of disease activity in axial spondyloarthritis | Adrian Ciurea, Raphael Micheroli |
| 2015_03 | Impact of axSpA on work participation and the role of anti-TNF treatment | Adrian Ciurea |
| 2015_09 | Analysis of fine anti-citrullinated peptide antibody specificities, anti-carbamylated peptide antibodies and genetic characteristics in psoriatic arthritis patients | Michael Nissen |
| 2017_08 | COmPASS II weather sensitivity | Ulrich Walker |
| 2018_02 | Patient reported outcomes in patients with axial spondyloarthritis and psoriatic arthritis starting treatment with TNF inhibitors: an analysis from the EuroSpA collaboration | Michael Nissen, Adrian Ciurea, Cem Gabay, Burkhard Moeller |
| 2018_03 | Retention and effectiveness of TNF inhibitor treatment in axial spondyloarthritis and psoriatic arthritis: an analysis from the EuroSpA collaboration | Michael Nissen, Adrian Ciurea, Cem Gabay, Burkhard Moeller |
| 2018_07 | Translating humoral immunity against apolipoprotein A1 from an emerging CV risk factor to cardiovascular risk stratification tool in IRD | Cem Gabay, Nicolas Vuilleumier |
| 2018_16 | Comparative efficacy of TNF-inhibitors (TNFi) versus other mode of action (OMA) biological DMARDs in PsA -- an observational study | Burkhard Moeller |
| 2019_04 | Multimodal-based disease activity indices und risk of progression in rheumatoid arthritis | Giorgio Tamborrini (now Pascal Zufferey), P. Mandl |
| 2019_08 | SYSCID: Discovering new biomarkers by large “multi-omics” analysis to identify individuals in pre-clinical stages of Rheumatoid Arthritis | C. Lamacchia, Axel Finckh |
| 2019_10 | Gender differences in Biologicals and targeted synthetic Disease Modifying Anti-Rheumatic Drugs in Spondyloarthritis and psoriatic arthritis | Michael Nissen, Adrian Ciurea, Burkhard Moeller |
| 2019_11 | European collaborative analysis of real-world effectiveness of JAKinhibs versus anti-TNF agents and other bDMARDs (Jak-pot) | Kim Lauper, HUG |
| 2019_13 | Development of a prediction score for response to biological or targeted synthetic DMARDs in patients with inflammatory rheumatic diseases by combining clinical and -omics data | Britta Maurer, Caroline Ospelt |
| 2019_16 | Predictors for loss of productivity and the effect of b/tsDMARD treatment on loss of productivity in Swiss patients with rheumatoid arthritis | Diego Kyburz |
| 2019_18 | SONAR SpA Validation study | Michael Nissen, Pascal Zufferey |
| 2019_22 | Response tolerance measures in rheumatology | Myriam Riek |
| 2020_01 | Prediction of erosions in RA by different modifications of the standard SONAR score | Burkhard Moeller |
| 2020_02 | The effectiveness of a therapeutic change in RA patients with radiographic progression despite low disease activity | Ruediger Mueller, Lena Brandt |
| 2020_03 | Risk factors of infection with SARS-CoV-2 and of a serious course of COVID-19 in inflammatory rheumatic diseases in Switzerland | Axel Finckh |
| 2020_04 | Effectiveness of Abatacept and alternative biologic antirheumatic agents according to the shared epitope: The EASE study | Axel Finckh |
| 2020_06 | Psoriasis and Axial Involvement in Spondyloarthritis | Adrian Ciurea |
| 2020_09 | Vaccination in patients with rheumatic diseases | Kim Lauper |
| 2020_11 | EuroSpA-D: Handling of missing component values in patient-reported outcomes | Stylianos Georgiadis, Myriam Riek, Swiss PI (Michael Nissen) |
| 2020_17 | Real-world dynamics of anti-S1-binding antibodies after COVID-19 vaccination in patients with inflammatory rheumatic diseases | Andrea Rubbert-Roth, Axel Finckh |
| 2020_19 | Enthesitis in psoriatic arthritis and axial spondyloarthritis: Pattern, risk factors, and effectiveness of tumor necrosis factor inhibitors - A EuroSpA collaboration study | Michael Nissen |
| 2020_20 | Treatment of peripheral arthritis in the spondyloarthritides: Joint-specific response to TNF inhibitors? | Adrian Ciurea |
| 2021_01 | Investigating drug-induced Chronic Kidney Disease using a pharmacogenomics approach in a multicentric framework Project | Alexander Leichtle, Burkhard Möller |
| 2021_02 | Is uveitis associated with a more severe axial disease phenotype in axial spondyloarthritis? | Adrian Ciurea |
| 2021_03 | Patient reported outcomes, drug adherence and clinical effectiveness of secukinumab in patients with psoriatic arthritis and axial spondylarthritis up to24 months: Results from the EuroSpA collaboration. | Burkhard Möller |
| 2021_04 | Understanding the heterogeneity in patient populations across EuroSpA registries - the role of national access and treatment guidelines | Michael Nissen |
| 2021_05 | Understanding the impact of COVID-19 on the anti-apoA-1 IgG response in inflammatory rheumatism disorders | Nicolas Vuilleumier, Axel Finckh |
| 2021_07 | Impact of national treatment guidelines, schedules of reimbursement and gross domestic product on treatment outcomes in patients treated with b/tsDMARDs across European observational spondyloarthritis registries | Adrian Ciurea |
| 2021_11 | Treatment retention in SpA patients assessed with methods for interval- censored time-to-event data | Myriam Riek, Seraphina Kissling, Adrian Ciurea |
| 2021_13 | Impact of the Covid-19 pandemic on patient selection and treatment outcomes in spondyloarthritis patients treated with b/tsDMARDs across Europe | Kim Lauper |
| 2021_14 | Impact of work-related physical stress on the response to different biologics in psoriatic arthritis | Raphael Micheroli |
| 2021_15 | Ultrasonographic differences of synovitis grade between joint locations in rheumatoid arthritis | Raphael Micheroli |
| 2022_01 | Gender-attributable differences in patient reported outcome measures in axial spondyloarthritis. | Raphael Micheroli |
| 2022_04 | Progression of sacroiliac joint and spinal structural changes in a European cohort of real-life patients with axial spondyloarthritis and psoriatic arthritis: A longitudinal analysis of magnetic resonance and X-ray images. | Adrian Ciurea, USZ |
| 2022_05 | Distribution of sacroiliac joint and spine imaging findings in a large cohort of real-life patients with axial SpA | Adrian Ciurea, USZ |
| 2022_06 | Local vs. central readings of MRIs of the sacroiliac joints in patients with axial spondyloarthritis: investigation of agreement and the need for educational activities for local interpreters” for your information | Adrian Ciurea, USZ |
| 2022_07 | Comparison of damage progression on MRI and conventional radiography of the sacroiliac joints in axial spondyloarthritis | Raphael Micheroli, USZ |
| 2022_08 | Investigation of ASDAS-ESR cut-offs values for disease activity states in axial spondyloarthritis | Adrian Ciurea, USZ |
| 2022_09 | EuroSpA area E: Data mapping survey study | Michael Nissen |
| 2022_11 | Automated Dorsal Finger Fold Pattern Recognition on Real World Hand Photos as a Potential Digital Biomarker for the activity of Rheumatoid Arthritis | Thomas Hugle |
| 2022_14 | Explore the impact of selected comorbidities and extraarticular manifestations on prescription patterns and treatment effectiveness | Michael Nissen |
| 2022_15 | Explore the incidence of adverse events in patients treated with conventional and/or biological DMARDs | Michael Nissen |
| 2022_16 | Chondrocalcinosis in Rheumatoid Arthritis: an imaging analysis on correlation with disease activity and radiographic progression of Osteoarthritis | Tobias Manigold, Thomas Hügle |
| 2022_17 | Mechanistic modelling-based prediction of humoral vaccine responses in immuno-modulated patients with inflammatory rheumatic diseases after mRNA COVID-19 vaccination | Christoph Berger, Andrea Rubbert-Roth |
| 2022_18 | The association between MRI sacroiliac joint and spine inflammation and structural lesions, physical function and spinal mobility, and other outcome measures | Adrian Ciurea, USZ |
| 2022_21 | Cohort profile: the SCQM polymyalgia rheumatica and giant cell arteritis cohort | Thomas Daikeler |
| 2022_22 | The MRI equivalent to modified New York criteria-positivity on conventional radiography of the sacroiliac joints | Adrian Ciurea, USZ |
| 2022_26 | Occurrence and pattern of MRI and radiographic involvement of sacroiliac joints and spine in a European cohort of real-life patients with psoriatic arthritis | Adrian Ciurea, USZ |
| 2023_03 | Therapeutic drug monitoring of JAK inhibitors as novel precision medicine instrument for acute and chronic inflammatory disorders | François Girardin |
| 2023_04 | Cross-country differences in bDMARD prescription behaviour: associations between socioeconomics, real world bDMARD use and disease outcomes | Delphine Courvoisier, HUG |
| 2023_05 | Early axial spondyloarthritis: Characterization, response to treatment and spinal radiographic progression in early vs. late disease | Adrian Ciurea, USZ |
| 2023_07 | Digital Biomarker for Monitoring and Predicting Disease Severity in the Daily Lives of Rheumatoid Arthritis Patients | Raphael Micheroli, USZ |
| 2023_10 | The role of the kynurenine pathway in regulating macrophage function in rheumatoid arthritis | Bojana Müller, Universitätsspital Basel |
| 2023_13 | A comparative cohort analysis of the time to treatment discontinuation and of the effectiveness of upadacitinib and tumor necrosis factor inhibitors in patients with rheumatoid arthritis: analysis of pooled data from RHUMADATA-OBRI-SCQM registries. | Denis Choquette, Axel Finckh, Claire Bombardier |
| 2023_17 | Comparison of DAS 28 (Disease Activity Score) and CDAI (Clinical Disease Activity Index)/ SDAI (Simplified Disease Activity Index) scores: Which score better assesses remission or low disease activity (LDA) in patients with rheumatoid arthritis? | Rüdiger Müller |
| 2023_24 | Validity and reliability of the Disease Activity index for Psoriatic Arthritis (DAPSA) and DAPSA-28 in European patients with Psoriatic Arthritis (PsA) | Michael Nissen |
| 2023_25 | Is peripheral joint response to IL-17 inhibition in the spondyloarthritides site-specific? A European cohort study in psoriatic arthritis and axial spondyloarthritis | Adrian Ciurea, USZ |
| 2023_27 | Differences of serum CHI3L1 and CHI3L2 in inflammatory arthritides and exploratory analysis of the prognostic value in rheumatoid arthritis | Raphael Micheroli, Caroline Ospelt |
| 2024_02 | Difficult-to-Manage (D2M) and treatment-refractory axial spondyloarthritis: Characterization and treatment outcomes | Adrian Ciurea, USZ |
| 2024_10 | Comparison of structural damage and damage progression on MRI and conventional radiography of the spine in axial spondyloarthritis | Adrian Ciurea, USZ |
| 2024_11 | Description of the different switching patterns involving biologics (b) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARDs), and evaluation of their effectiveness in axSpA and PsA: results from the EuroSpA Research collaboration Network. | Adrian Ciurea, USZ |
| 2024_13 | A comparative cohort analysis of the time to treatment discontinuation and of the effectiveness of upadacitinib and tumor necrosis factor inhibitors in patients with rheumatoid arthritis: analysis of pooled data from RHUMADATA-OBRI-SCQM registries | Axel Finckh, Denis Chocquette |
| 2024_18 | Joint-level responses in rheumatoid arthritis | Adrian Ciurea, USZ |
Les projets de coopération internationale ne sont mentionnés qu'à titre indicatif. Veuillez noter que l'intégration de collaborateurs supplémentaires dans les projets internationaux n'est souvent pas possible, car la taille du groupe de projet est limitée par pays.